
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company with a strong focus on the development of products to treat ADHD and anxiety using its proprietary drug delivery platform, PTR technology. With the recent return of CEO Shane Schaffer and the potential approval of its first-line stimulant medications in mid-2026 with commercialization in late-2026, the stock is well-positioned for future success. Risks must be taken into consideration, but potential approval in mid or late-2026 and commercialization in late-2026 or early 2027 would likely have a positive impact on the company's financials and drive investor sentiment.
Bears say
Cingulate is a clinical-stage biopharmaceutical company with a focus on ADHD and anxiety treatments. While the company's PTR drug delivery platform shows potential for once-daily dosing of multi-dose therapies, their success relies heavily on the market acceptance and pricing of their proprietary stimulant medications. Without a diverse pipeline and revenue sources, the company's future financial stability is uncertain.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares